An ink includes water, a compound represented by the following Chemical formula 1, Pigment Red 269 represented by the following Chemical formula 2, and alkylene glycol alkyl ether, wherein the proportion of the compound represented by the following Chemical formula 1 in a total amount of the Pigment Red 269 is 2 or less percent by mass. ##STR00001##

An ink includes water, a compound represented by the following Chemical formula 1, Pigment Red 269 represented by the following Chemical formula 2, and alkylene glycol alkyl ether, wherein the proportion of the compound represented by the following Chemical formula 1 in a total amount of the Pigment Red 269 is 2 or less percent by mass. ##STR00001##

An ink includes water, a compound represented by the following Chemical formula 1, Pigment Red 269 represented by the following Chemical formula 2, and alkylene glycol alkyl ether, wherein the proportion of the compound represented by the following Chemical formula 1 in a total amount of the Pigment Red 269 is 2 or less percent by mass.

##STR00001##

An ink includes water, a compound represented by the following Chemical formula 1, Pigment Red 269 represented by the following Chemical formula 2, and alkylene glycol alkyl ether, wherein the proportion of the compound represented by the following Chemical formula 1 in a total amount of the Pigment Red 269 is 2 or less percent by mass.

##STR00001##

Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.

Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.

Alterations to the ERG gene are some of the most prominent genomic changes associated with many cancers including prostate cancer. Such cancer specific alterations result in the overexpression of wild type ERG protein or an altered ERG protein. The present invention provides selective inhibitors of wild type or an altered ERG protein expression. The ERG inhibitors of the invention, therefore, are therapeutic agents for treating ERG positive cancers.